<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02302508</url>
  </required_header>
  <id_info>
    <org_study_id>14.143</org_study_id>
    <nct_id>NCT02302508</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients</brief_title>
  <acronym>PANDDA</acronym>
  <official_title>PANDDA Study: Pharmacokinetics of Antiplatelet Drugs in Diabetic pAtients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre hospitalier de l'Université de Montréal (CHUM)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Centre de Recherche du Centre Hospitalier de l'Université de Montréal</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre hospitalier de l'Université de Montréal (CHUM)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Clopidogrel efficacy appears diminished in patients with type 2 diabetes (T2D) who continue&#xD;
      to show an increased risk of adverse cardiovascular events and mortality compared to those&#xD;
      without T2D.The aim of the first project is to describe the pharmacokinetic (PK) profile of&#xD;
      three antiplatelet drugs in 4 groups of patients according to their diabetic or non-diabetic&#xD;
      status. To this end, PK profiles will be determined after a single oral dose of 300 mg&#xD;
      clopidogrel, 60 mg prasugrel and 180 mg ticagrelor in patients (n=108); 1) with T2D and good&#xD;
      glycemic control; 2) with T2D and poor glycemic control; 3) with insulin-treated diabetes;&#xD;
      and 4) non-diabetic subjects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Clopidogrel efficacy appears diminished in patients with T2D who continue to show an&#xD;
      increased risk of adverse cardiovascular events and mortality compared to those without T2D.&#xD;
      To the contrary, response to prasugrel and ticagrelor appears conserved in ACS patients with&#xD;
      diabetes. There are several mechanisms that may be contributing to the blunted response to&#xD;
      clopidogrel but a postulated decreased concentration of clopidogrel active metabolite is&#xD;
      worth pursuing further.&#xD;
&#xD;
      The overall objective of this proposal is to describe the pharmacokinetic profiles of three&#xD;
      antiplatelet drugs namely, clopidogrel, prasugrel and ticagrelor in four groups of patients&#xD;
      according to their diabetic or non-diabetic status.&#xD;
&#xD;
      Patients (n=108) will be recruited to constitute 4 groups: Group I, 27 confirmed T2D with A1C&#xD;
      ≤7; Group II, 27 patients with poor glycemic control A1C Patients (n=108) will be recruited&#xD;
      to constitute 4 groups: Group I, 27 confirmed T2D with A1C &lt;7.0; Group II, 27 patients with&#xD;
      poor glycemic control A1C &gt;7.5; Group III, 27 patients with insulin-treated T2D; and Group&#xD;
      IV, 27 sex-matched non-diabetic healthy subjects. Subjects with type 2 diabetes according to&#xD;
      the Canadian Clinical Guidelines will be recruited at the CHUM outpatient clinic. After an&#xD;
      overnight fast, participants will be admitted to the CRCHUM's Clinical Research Unit (they&#xD;
      will not be hospitalized). A crossover randomized study design with 3 phases (washout period&#xD;
      of 12 days between phases) will be conducted. Subjects will receive a single oral dose of&#xD;
      clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3&#xD;
      different occasions. Serial blood samples will be drawn and urine collected over 10 hours (PK&#xD;
      and PD analysis).&#xD;
&#xD;
      A blood sample will be taken for pharmacogenetic analyses. Additional blood samples will be&#xD;
      collected just before the administration of antiplatelet drugs to measure fasting insulin,&#xD;
      glycaemia levels to determine the HOMA-IR. In addition, the following covariates namely,&#xD;
      gender, age, weight, duration of diabetes and drug profile will be also recorded.&#xD;
&#xD;
      Their regular medication will be administered 4 hours after the administration of the&#xD;
      antiplatelet drug.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    Funding&#xD;
  </why_stopped>
  <start_date type="Anticipated">September 1, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (AUC0-t metabolites and parent drug) of clopidogrel, prasugrel and ticagrelor.</measure>
    <time_frame>30 days</time_frame>
    <description>The association between the T2D effects on antiplatelet drug's PK (AUC0-t metabolites, AUC0-t of parent drug) will be assessed after a single oral loading dose in patients with different diabetic status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Platelet function activities</measure>
    <time_frame>30 days</time_frame>
    <description>Platelet function reactivity (pharmacodynamic) will be compared between antiplatelet agents and groups of patients.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>T2D patients with A1C ≤7.0</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2D patients with A1C&gt;7.5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulino-treated</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-diabetic healthy subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Clopidogrel, Prasugrel, Ticagrelor A single oral dose of clopidogrel 300 mg or prasugrel 60 mg or ticagrelor 180 mg in a randomized fashion on 3 different occasions (washout period of 12 days or more)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clopidogrel, Prasugrel, Ticagrelor</intervention_name>
    <description>PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents</description>
    <arm_group_label>Insulino-treated</arm_group_label>
    <arm_group_label>Non-diabetic healthy subjects</arm_group_label>
    <arm_group_label>T2D patients with A1C ≤7.0</arm_group_label>
    <arm_group_label>T2D patients with A1C&gt;7.5</arm_group_label>
    <other_name>Plavix</other_name>
    <other_name>Brilinta</other_name>
    <other_name>Effient</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants will be ≥18 years old&#xD;
&#xD;
          -  Non-smokers (&gt;3 months)&#xD;
&#xD;
          -  T2D with good glycemic control A1C&lt;7.0&#xD;
&#xD;
          -  T2D with poor glycemic control A1C &gt;7.5&#xD;
&#xD;
          -  Insulin-treated T2D&#xD;
&#xD;
          -  Non-diabetic healthy subjects&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects with estimated glomerular filtration (MDRD) &lt;50 mL/min/1.73m2&#xD;
&#xD;
          -  ALT and AST 3 times above the upper limit of normal&#xD;
&#xD;
          -  Organ transplant recipients&#xD;
&#xD;
          -  Inflammatory illnesses (i.e., polyarthritis, hepatitis, cirrhosis, active infectious&#xD;
             diseases)&#xD;
&#xD;
          -  Active cancer (except non-melanoma skin cancer)&#xD;
&#xD;
          -  Uncontrolled thyroid functions&#xD;
&#xD;
          -  Inflammatory bowel diseases (ulcerous colitis and Crohn's disease), bariatric surgery&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  History of drug or alcohol abuse&#xD;
&#xD;
          -  Platelet function disorder,&#xD;
&#xD;
          -  One of the following therapies : P2Y12 inhibitors, antithrombotics, antibiotics,&#xD;
             anticoagulant, antivirals, CYP450 inducers (carbamazepine, phenobarbital, phenytoin,&#xD;
             rifampin, St-John's worth), CYP450 inhibitors (amiodarone, fluoxetine, verapamil),&#xD;
             immunosuppressors, INFs, or grapefruit juice (&lt;4 weeks) or an investigational drug&#xD;
&#xD;
          -  Intolerance or hypersensitivity to antiplatelet drugs or their excipients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Veronique Michaud, BPharm. PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de recherche du Centre Hospitalier de l'université de Montréal (CHUM)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre hospitalier de l'Université de Montréal (CHUM)</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X0A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>November 11, 2014</study_first_submitted>
  <study_first_submitted_qc>November 24, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2014</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacokinetics</keyword>
  <keyword>drug metabolism</keyword>
  <keyword>platelet reactivity</keyword>
  <keyword>carboxylesterase</keyword>
  <keyword>cytochromes p450</keyword>
  <keyword>type 2 diabetes</keyword>
  <keyword>active metabolite</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clopidogrel</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
    <mesh_term>Prasugrel Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

